Literature DB >> 2300240

Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement.

A G Kermode1, P S Tofts, A J Thompson, D G MacManus, P Rudge, B E Kendall, D P Kingsley, I F Moseley, E P du Boulay, W I McDonald.   

Abstract

We performed 15 dynamic gadolinium-DTPA (Gd-DTPA)-enhanced MRI studies in 8 patients with relapsing and remitting multiple sclerosis; 7 were follow-up studies. We measured the time course of enhancement in 102 enhancing lesions for up to 384 minutes, with rest breaks. Immediate postcontrast MRIs demonstrated many different patterns of enhancement. We observed both uniformly enhancing and ring enhancing lesions. The enhancing regions were often less extensive than the corresponding high signal on T2-weighted images. Three lesions were seen with Gd-DTPA but not on unenhanced scans; 1 was seen on unenhanced scans 10 days later, suggesting that blood-brain barrier disturbance may precede other MRI signs of MS lesions. Three months later, some high-signal areas on T2-weighted scans had decreased in size to resemble the areas previously outlined by Gd-DTPA. This technique provides useful information about the pathogenesis and behavior of MS lesions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2300240     DOI: 10.1212/wnl.40.2.229

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  38 in total

1.  Population-wide principal component-based quantification of blood-brain-barrier dynamics in multiple sclerosis.

Authors:  Russell T Shinohara; Ciprian M Crainiceanu; Brian S Caffo; María Inés Gaitán; Daniel S Reich
Journal:  Neuroimage       Date:  2011-05-23       Impact factor: 6.556

2.  Towards quantitative measurements of relaxation times and other parameters in the brain.

Authors:  P S Tofts; E P du Boulay
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

3.  Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging.

Authors:  F Barkhof; P Scheltens; J Valk; C Waalewijn; B M Uitdehaag; C H Polman
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

4.  Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.

Authors:  D H Miller; F Barkhof; I Berry; L Kappos; G Scotti; A J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

5.  Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability.

Authors:  Sonia Chalbot; Henrik Zetterberg; Kaj Blennow; Tormod Fladby; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Neurosci Lett       Date:  2010-05-12       Impact factor: 3.046

6.  High-dose contrast-enhanced MRI in multiple sclerosis.

Authors:  T Koudriavtseva; C Pozzilli; C Di Biasi; M Iannilli; G Trasimeni; C Gasperini; C Argentino; G F Gualdi
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

7.  Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?

Authors:  J Pakpoor; D Saylor; I Izbudak; L Liu; E M Mowry; D M Yousem
Journal:  AJNR Am J Neuroradiol       Date:  2016-10-06       Impact factor: 3.825

8.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.

Authors:  Y Qin; P Duquette; Y Zhang; P Talbot; R Poole; J Antel
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

9.  Initial investigation of the blood-brain barrier in MS lesions at 7 tesla.

Authors:  María I Gaitán; Pascal Sati; Souheil J Inati; Daniel S Reich
Journal:  Mult Scler       Date:  2012-12-17       Impact factor: 6.312

Review 10.  Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers.

Authors:  Fabien Chauveau; Hervé Boutin; Nadja Van Camp; Frédéric Dollé; Bertrand Tavitian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-10-01       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.